Clinical Trials

272 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT04452591 2026-03-16

BOND-003

190 enrolled

Non-Muscle Invasive Bladder Neoplasms, Carcinoma in Situ

NCT06995677 2026-03-16

SURF302

90 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT05316155 2026-03-13

Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer

235 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT06319820 2026-03-13

MoonRISe-1

Phase 3 Recruiting

641 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT06919965 2026-03-13

MoonRISe-3

Phase 3 Recruiting

220 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT07309445 2026-03-13

Nova-sTAR

Recruiting

150 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT07206225 2026-03-11

A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer

Phase 1 Recruiting

294 enrolled

Phase 3 Not yet recruiting

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT07464145 2026-03-11

RESCUE

393 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Neoplasms, Urologic Neoplasms

NCT06443944 2026-03-06

An Expanded Access Program of Cretostimogene Grenadenorepvec for Treatment of NMIBC for Patients Unresponsive to BCG

Available

Phase 1/2 Not yet recruiting

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Urologic Neoplasms

NCT07445308 2026-03-03

The Study is to Evaluate the Safety and Tolerability of SPGL008 Alone or in Combination With BCG in the Patients With NMIBC, and to Determine the RP2D of SPGL008 Alone or in Combination With BCG.To Evaluate the Preliminary Efficacy of SPGL008 Alone or in Combination With BCG.

120 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT04172675 2026-02-24

A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)

Phase 2 Completed

107 enrolled 17 charts

Phase 3 Not yet recruiting

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT07424287 2026-02-20

A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC

236 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT06637423 2026-02-19

TroFuse-027

32 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT06026332 2026-02-17

ABLE-41

Terminated

202 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT06877676 2026-02-13

Pre-Approval Expanded Access Study for TAR-200 Treating Physician Use

Approved for marketing

Non-Muscle Invasive Bladder Neoplasms

NCT05951179 2026-01-27

ADVANCED-2

131 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ

NCT04752722 2026-01-26

LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

350 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ

NCT04165317 2026-01-22

CREST

1,068 enrolled 20 charts

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT07283835 2026-01-21

Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin

16 enrolled

Non-Muscle Invasive Bladder Neoplasms, Carcinoma in Situ

NCT06331299 2026-01-15

UTOPIA

99 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT05375903 2026-01-14

A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)

Phase 1 Completed

51 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT06810141 2026-01-14

ResQ132EX-NMIBC: Expanded Access Use of Recombinant Bacillus Calmette-Guérin in Nonmuscle Invasive Bladder Cancer

Available

Phase 1/2 Active not recruiting

Non-Muscle Invasive Bladder Neoplasms

NCT05544552 2026-01-12

SURF301

310 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasm Metastasis, Urologic Neoplasms

NCT06111235 2026-01-12

A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT

367 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Urologic Neoplasms

NCT07144319 2025-12-26

ENAiBLE

Not yet recruiting

500 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT02660645 2025-12-18

BLCCR

Recruiting

4,400 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT03528694 2025-11-25

POTOMAC

1,018 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT03945162 2025-11-24

Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients

90 enrolled

Phase NA Not yet recruiting

Non-Muscle Invasive Bladder Neoplasms, Carcinoma, Transitional Cell

NCT07231809 2025-11-21

HIVEC

50 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma

NCT05014139 2025-11-20

A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)

Phase 1 Terminated

37 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell

NCT02138734 2025-10-16

A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer

596 enrolled

Phase 2/3 Active not recruiting

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasms

NCT03022825 2025-10-16

QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer

190 enrolled 1 FDA

Phase 2 Not yet recruiting

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT06829823 2025-10-16

Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder Cancer

20 enrolled

Phase 1 Active not recruiting

Non-Muscle Invasive Bladder Neoplasms

NCT06181266 2025-08-19

PARADIGM-1

22 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT02106572 2025-07-23

TIM

548 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT06816017 2025-06-16

A Study to Evaluate Eciskafusp Alfa in Combination With Bacillus Calmette-guerin (BCG) in Participants With BCG-unresponsive High-risk Non-muscle Invasive Bladder Cancer (NMIBC)

Phase 1 Withdrawn

Non-Muscle Invasive Bladder Neoplasms

NCT06663137 2025-06-13

HGNMIBC

70 enrolled

Phase NA Not yet recruiting

Non-Muscle Invasive Bladder Neoplasms

NCT06678633 2025-05-29

T-Control® Safety for Cytostatics Management

16 enrolled

Phase 1/2 Not yet recruiting

Non-Muscle Invasive Bladder Neoplasms

NCT06800963 2025-05-16

ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG

40 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT05945108 2025-04-11

Brazilian Reality of Urinary Bladder Cancers - BRA-BLADDER

Completed

400 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT05981131 2025-03-13

Follow up of Intravesical N-803 Plus BCG in BCG-Naive Non-Muscle Invasive Bladder Cancer (NMIBC)

Active not recruiting

6 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT05085977 2025-01-27

ADVANCED-1

Phase 1 Completed

12 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ

NCT05085990 2025-01-27

ADVANCED-1

Phase 1 Completed

10 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ

NCT06186414 2025-01-15

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SIM0237 Alone or in Combination with BCG in NMIBC

Phase 1 Recruiting

152 enrolled

DermatologicGastrointestinalGenitourinaryThoracic

Non-Muscle Invasive Bladder Neoplasms

NCT06448364 2024-11-06

LTbR

Phase 1 Terminated

4 enrolled

Non-Muscle Invasive Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasm Metastasis, Colorectal Neoplasms

NCT05243550 2024-11-04

ENVISION

240 enrolled 20 charts 1 FDA

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT04690699 2024-10-24

LUMINOS-103: A Basket Trial of Safety & Efficacy of Lerapolturev With or Without Checkpoint Inhibitors

Phase 1/2 Terminated

4 enrolled 6 charts

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT04387461 2024-09-25

CORE-001

Phase 2 Completed

35 enrolled